RT Journal Article
SR Electronic
T1 Rapid epidemic expansion of chikungunya virus-ECSA lineage in Paraguay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.16.23288635
DO 10.1101/2023.04.16.23288635
A1 Giovanetti, Marta
A1 Vazquez, Cynthia
A1 Lima, Mauricio
A1 Castro, Emerson
A1 Rojas, Analia
A1 de la Fuente, Andrea Gomez
A1 Aquino, Carolina
A1 Cantero, Cesar
A1 Fleitas, Fatima
A1 Torales, Juan
A1 Barrios, Julio
A1 Ortega, Maria Jose
A1 Gamarra, Maria Liz
A1 Villalba, Shirley
A1 Alfonzo, Tania
A1 Xavier, Joilson
A1 Adelino, Talita
A1 Fritsch, Hegger
A1 Iani, Felipe C. M.
A1 Pereira, Glauco Carvalho
A1 de Oliveira, Carla
A1 Schuab, Gabriel
A1 Rodrigues, Evandra Strazza
A1 Kashima, Simone
A1 Leite, Juliana
A1 Gresh, Lionel
A1 Franco, Leticia
A1 Tegally, Houriiyah
A1 Van Voorhis, Wesley C.
A1 Lessels, Richard
A1 de Filippis, Ana Maria Bispo
A1 Ojeda, Andrea
A1 Sequera, Guillermo
A1 Montoya, Romeo
A1 Holmes, Edward C.
A1 de Oliveira, Tulio
A1 Rico, Jairo Mendez
A1 Lourenço, José
A1 Fonseca, Vagner
A1 Junior Alcantara, Luiz Carlos
YR 2023
UL http://medrxiv.org/content/early/2023/04/17/2023.04.16.23288635.abstract
AB The spread of vector-borne viruses, such as CHIKV, is a significant public health concern in the Americas, with over 120,000 cases and 51 deaths in 2023, of which 46 occurred in Paraguay. Using a suite of genomic, phylodynamic, and epidemiological techniques, we characterized the ongoing large CHIKV epidemic in Paraguay.Article Summary Line Genomic and epidemiological characterization of the ongoing Chikungunya virus epidemic in ParaguayCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the PAHO Health Emergencies Department, by the National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), FAPESP (2021/11944-6) and by Mercosur Structural Convergence Fund (FOCEM), Mercosur, FOCEM agreement N 03/11 Project "Research, Education and Biotechnologies Applied to Health (COF 03/11).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was reviewed and approved by the Pan American Health Organization Ethics Review Committee (PAHOERC) (Ref. No. PAHO-2016-08-0029) and by the Paraguayan Ministry of Public Health and Social Welfare (MSPyBS/ S.G. no. 0944/18). The samples used in this study were de-identified residual samples from the routine diagnosis of arboviruses in the Paraguayan public health laboratory, which is part of the public network within the Paraguayan Ministry of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenBank, accession number OQ775394-OQ775567 and OQ567722-OQ567725